Next Capital Management LLC Acquires Shares of 13,046 ARK Genomic Revolution ETF $ARKG

Next Capital Management LLC bought a new stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 13,046 shares of the company’s stock, valued at approximately $318,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Private Wealth Asset Management LLC lifted its position in ARK Genomic Revolution ETF by 70.0% during the 2nd quarter. Private Wealth Asset Management LLC now owns 1,275 shares of the company’s stock valued at $31,000 after acquiring an additional 525 shares during the period. Headlands Technologies LLC bought a new position in shares of ARK Genomic Revolution ETF during the first quarter valued at approximately $45,000. UMB Bank n.a. purchased a new position in shares of ARK Genomic Revolution ETF during the second quarter valued at approximately $87,000. ARK Investment Management LLC lifted its holdings in shares of ARK Genomic Revolution ETF by 11.0% during the second quarter. ARK Investment Management LLC now owns 4,321 shares of the company’s stock valued at $105,000 after purchasing an additional 429 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of ARK Genomic Revolution ETF by 49.4% in the 1st quarter. NewEdge Advisors LLC now owns 5,384 shares of the company’s stock worth $112,000 after purchasing an additional 1,780 shares in the last quarter.

ARK Genomic Revolution ETF Stock Performance

ARK Genomic Revolution ETF stock opened at $30.67 on Tuesday. ARK Genomic Revolution ETF has a twelve month low of $17.51 and a twelve month high of $31.16. The stock’s 50 day moving average is $28.38 and its 200 day moving average is $25.16.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.